Group 1 - Pfizer (PFE) experienced a 4% decline in early trading on Tuesday [1][2] - The company reported better-than-expected results for the fourth quarter, but saw a decrease in sales of COVID-19 products [1][2] - Pfizer issued a conservative earnings guidance and maintained its expectations for 2026 [1][2] - The company strengthened its obesity drug pipeline through the Metsera transaction [1][2]